Scholarlink

<p>To explore the regulatory impacts of the probiotic strain <i>Weizmannia coagulans</i> BC-G44 on antibiotic-associated diarrhea (AAD) and the gut microbiota, a mouse model was established. Twenty-four male C57BL/6 mice were selected and randomly divided into four antibiotic treatment groups: normal, model, high-dose, and low-dose. The normal group mice received 0.2&#xa0;mL normal saline twice a day, while the model, high-dose, and low-dose groups received 0.2&#xa0;mL of an antibiotic mixture (550&#xa0;mg∙kg<sup>−1</sup> amoxicillin, 450&#xa0;mg∙kg<sup>−1</sup> clindamycin, 400&#xa0;mg∙kg<sup>−1</sup> streptomycin) twice daily to reduce AAD. For the following 5&#xa0;days, the high-dose and low-dose groups received <i>W. coagulans</i> BC-G44 at 10<sup>9</sup> and 10<sup>7</sup> colony-forming units/mL/day, respectively. On the final day, all mice were euthanized for collection of feces, serum, colon and cecum tissues, and cecal contents. <i>W. coagulans</i> BC-G44 alleviated the weight loss and lowered the serum concentrations of lipopolysaccharide and tumor necrosis factor-α, activating the inflammatory response. <i>W. coagulans</i> BC-G44 also significantly reduced the inflammatory cell infiltration and intestinal mucosal injury in the colon and increased the mRNA expression of the Occludin and ZO-1 genes. Furthermore, 16S rRNA sequencing revealed that <i>W. coagulans</i> BC-G44 increased the gut microbiota diversity of AAD mice, with alpha diversity and beta diversity analyses indicating significant differences in species composition between model and <i>W. coagulans</i> BC-G44-treated groups. Among the AAD mice, BC-G44 reduced the relative abundances of <i>Escherichia</i> and <i>Robinsoniella</i> in the low-dose group and <i>Klebsiella</i> in the high-dose group. Metabolomics of <i>W. coagulans</i> BC-G44 culture supernatants, including untargeted metabolites and Kyoto Encyclopedia of Genes and Genomes pathway annotations, revealed changes in metabolic pathways and metabolites relevant to mice. Our findings indicated that <i>W. coagulans</i> BC-G44 alleviates the AAD process in mice by relieving diarrhea symptoms, easing intestinal inflammation, altering intestinal permeability, and improving gut microbiota structure.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Regulating Effect of Weizmannia coagulans BC-G44 on Antibiotic-Associated Diarrhea and its Improvement on Gut Microbiota

  • 期刊论文

  • 发表日期：

    2025年10月27日

查看全文
  • Zhouyi Wang,
  • Yinghan Xiang,
  • Yafang Xu,
  • Jiaxin An,
  • Qianrui Wei,
  • Yang Chen,
  • Di Han,
  • Zhanxi Hao,
  • Huajun Li

摘要

To explore the regulatory impacts of the probiotic strain Weizmannia coagulans BC-G44 on antibiotic-associated diarrhea (AAD) and the gut microbiota, a mouse model was established. Twenty-four male C57BL/6 mice were selected and randomly divided into four antibiotic treatment groups: normal, model, high-dose, and low-dose. The normal group mice received 0.2 mL normal saline twice a day, while the model, high-dose, and low-dose groups received 0.2 mL of an antibiotic mixture (550 mg∙kg−1 amoxicillin, 450 mg∙kg−1 clindamycin, 400 mg∙kg−1 streptomycin) twice daily to reduce AAD. For the following 5 days, the high-dose and low-dose groups received W. coagulans BC-G44 at 109 and 107 colony-forming units/mL/day, respectively. On the final day, all mice were euthanized for collection of feces, serum, colon and cecum tissues, and cecal contents. W. coagulans BC-G44 alleviated the weight loss and lowered the serum concentrations of lipopolysaccharide and tumor necrosis factor-α, activating the inflammatory response. W. coagulans BC-G44 also significantly reduced the inflammatory cell infiltration and intestinal mucosal injury in the colon and increased the mRNA expression of the Occludin and ZO-1 genes. Furthermore, 16S rRNA sequencing revealed that W. coagulans BC-G44 increased the gut microbiota diversity of AAD mice, with alpha diversity and beta diversity analyses indicating significant differences in species composition between model and W. coagulans BC-G44-treated groups. Among the AAD mice, BC-G44 reduced the relative abundances of Escherichia and Robinsoniella in the low-dose group and Klebsiella in the high-dose group. Metabolomics of W. coagulans BC-G44 culture supernatants, including untargeted metabolites and Kyoto Encyclopedia of Genes and Genomes pathway annotations, revealed changes in metabolic pathways and metabolites relevant to mice. Our findings indicated that W. coagulans BC-G44 alleviates the AAD process in mice by relieving diarrhea symptoms, easing intestinal inflammation, altering intestinal permeability, and improving gut microbiota structure.